-
Effects of Lisinopril and Amlodipine in Combination for the Treatment of Hypertension with Pulse Wave Velocity VP Plus 1000 Meter
Cao Truong Sinh,
Hoang Ngoc Linh
Issue:
Volume 10, Issue 3, May 2022
Pages:
67-73
Received:
24 April 2022
Accepted:
7 May 2022
Published:
12 May 2022
Abstract: Aim: The aim of this study was to evaluate the antihypertensive efficacy of lisinopril and amlodipine in combination which were measured by the pulse wave velocity meter. Research objects and Methods: 40 patients with primary hypertension, mean age 69.18 ± 10.4 years. All patients had their blood pressure, pulse wave velocity (baWPV), ankle brachial index measured by pulse wave velocity VP Plus 1000 meter before receiving the treatment. All patients were then given the Lisonorm combination pill (lisinopril 10 mg and amlodipine 5 mg) for 4 weeks. After 4 weeks, the patients was measured again with the same device (the pulse wave velocity of VP Plus 1000 meter). Results: After 4 weeks, the values of the Right arm blood pressure decreased: 26.58 ± 9.51 mmHg/ 8.6 ± 4.47 mmHg; Left arm blood pressure decreased: 26.88 ± 11.27/13.55 ± 8.15mmHg; Right ankle blood pressure decreased: 23.75 ± 11.78/10.75 ± 6.64mmHg; Left ankle blood pressure decreased: 30.33 ± 16.64/13.6 ± 9.28mmHg; The rate of patients with the target blood pressure was 72.5% (29/40 patients). Right baPWV decreased 593.65 ± 416.59 cm/s; Left baPWV decreased 585.4 ± 447.19 cm/s. Conclusion: The combination of lisinopril 10mg and amlodipine 5mg effectively had decreased the blood pressure in both extremities and pulse wave velocity, and had reduced vessel wall stiffness when it was measured by the pulse wave velocity VP Plus 1000 meter.
Abstract: Aim: The aim of this study was to evaluate the antihypertensive efficacy of lisinopril and amlodipine in combination which were measured by the pulse wave velocity meter. Research objects and Methods: 40 patients with primary hypertension, mean age 69.18 ± 10.4 years. All patients had their blood pressure, pulse wave velocity (baWPV), ankle brachia...
Show More
-
Optimization of Ovarian Stimulation After Preparation with Oral Hormonal Contraceptives
Guijarro Guedes Jesús,
Santana Suárez Alejandra,
Álvarez Sánchez Mónica,
Roldán Gutiérrez Lourdes,
Benítez Castillo Nelda,
Tabares Concepción José,
Sánchez Sánchez Victoria,
Martin Martínez Alicia
Issue:
Volume 10, Issue 3, May 2022
Pages:
74-78
Received:
25 October 2021
Accepted:
17 March 2022
Published:
12 May 2022
Abstract: Introduction: Ovarian stimulation can be performed in early follicular phase or after pretreatment with OCPs. The aim of this study is to know if OCPs prior to ovarian stimulation improve the results in an IVF cycle. Material and methods: Retrospective case-control study. We included 132 patients (aged 18-40 years) undergoing two consecutive IVF-ICSI cycles (264 cycles). One cycle was initiated without pretreatment and the other after pretreatment with dienogest 2 mg/etinylestradiol 0.03 mg. The dose and type of gonadotropins used was adjusted according to age, body mass index and antral follicle count. During ovarian stimulation, serial ultrasound and analytical controls were performed until the day of ovulation induction and puncture programming. Results: There were statistically significant differences in gestation rates with a higher number of pregnancies in the OCPs group (37.18% vs. 13.95%, p=0.005). The live newborn rate was higher in the group of patients prepared with OCPs (30.77% vs. 5.81%, p=0.005). Total days of stimulation was lower in the OCPs group (8.50 vs. 9.13, p=0.000). There were no statistically significant differences in the total number of oocytes retrieved, metaphase II oocytes or embryo quality. Conclusions: the use of OCPs can be considered as a pre-treatment in an IVF cycle since it allows us to plan ovarian stimulation without worsening the live birth rate.
Abstract: Introduction: Ovarian stimulation can be performed in early follicular phase or after pretreatment with OCPs. The aim of this study is to know if OCPs prior to ovarian stimulation improve the results in an IVF cycle. Material and methods: Retrospective case-control study. We included 132 patients (aged 18-40 years) undergoing two consecutive IVF-IC...
Show More
-
Considerations on the Design Strategy of Professional Big Data Cloud Platform for Chest Pain Center
Jian Yao,
Mingxiao Hou,
Limin Liu,
Shuai Wang,
Chunjian Shen,
Yanhui Cui
Issue:
Volume 10, Issue 3, May 2022
Pages:
79-82
Received:
24 May 2022
Published:
26 May 2022
Abstract: The establishment of a professional big data cloud platform with the chest pain center as the core can not only collect, process and analyze various types of rapidly changing mass data in the clinical work of the chest pain center in real time, but also provide personalized services to individuals and connect individuals, hospitals and health management institutions through the mobile Internet channel. This paper summarizes and proposes matters that should be noted in building this platform: The design should focus on the actual business operation and management requirements and meet the infrastructure requirements of the big data cloud platform. It should be considered as a whole from the regional level to the hospital level, and the architecture design and standards should be considered vertically and horizontally; It is recommended to unify patient identification numbers and to be compatible with existing data systems. At the initial stage of the construction of the cloud platform, a tertiary hospital should be the core, and all kinds of medical resources such as hospitals, nursing institutions, nursing homes and pharmacies at all levels should be gradually opened. The functional integration design strategy of the chest pain center workstation should be integrated with the electronic medical record system as the core, making full use of the original PACS system and equipment of the hospital to automatically collect time trajectory and examination data of the whole process of patient's medical treatment. Meet the hospital's quality control and management needs of the platform. The ultimate goal is to reduce the mortality of patients with chest pain.
Abstract: The establishment of a professional big data cloud platform with the chest pain center as the core can not only collect, process and analyze various types of rapidly changing mass data in the clinical work of the chest pain center in real time, but also provide personalized services to individuals and connect individuals, hospitals and health manag...
Show More
-
Effects of Nischarin on the Migration Ability of Hepatocellular Carcinoma Cells
Guofen Zheng,
Xuyi Lin,
Bingwei Yu,
Juncheng Yu,
Xin Wang,
Aiqing Li,
Yuemin Ding
Issue:
Volume 10, Issue 3, May 2022
Pages:
83-87
Received:
31 May 2022
Published:
1 June 2022
Abstract: To clarify the effect of Nischarin on the biological behavior of hepatocellular carcinoma cells, two human hepatocellular carcinoma cell lines QGY-7701 and HepG2 were selected. The migration ability of the cells was determined with human normal hepatocyte LO2 as control. Western blotting was used to detect the differential expression of Nischarin and its downstream signals. The expression of Nischarin was knocked down by plasmid transfection to study the changes of cell migration ability, so as to evaluate the effect of Nischarin on hepatocellular carcinoma cells. The results of cell scratch experiment showed that compared with LO2 cells, the migration ability of HepG2 was significantly enhanced (P < 0.05), but there was no significant difference in the migration ability between QGY-7701 and LO2 cells. The results of Western blotting showed that the expression of Nischarin in HepG2 was significantly lower than that in LO2 cells (P < 0.05). Quantitative RT-PCR was used to detect the mRNA level of Nischarin in cells and found that the Nischarin mRNA level of HepG2 was significantly lower than that of LO2 (P < 0.01). When HepG2 cells were transfected with Nis-shRNA to knock down the expression of Nischarin, the cell migration ability was significantly increased (P < 0.05). While Nischarin overexpression significantly inhibited the phosphorylation of LIMK1 and cofilin, the important molecules of Rho-GTPase signaling pathway. These results strongly suggest that Nischarin is an endogenous protein with the ability to inhibit the migration of hepatocellular carcinoma cells. In conclusion, we found a protein that can inhibit the migration of hepatocellular carcinoma cells, which may have potential value in the diagnosis and treatment of hepatocellular carcinoma, but its molecular mechanism needs to be further studied.
Abstract: To clarify the effect of Nischarin on the biological behavior of hepatocellular carcinoma cells, two human hepatocellular carcinoma cell lines QGY-7701 and HepG2 were selected. The migration ability of the cells was determined with human normal hepatocyte LO2 as control. Western blotting was used to detect the differential expression of Nischarin a...
Show More
